Optimal Definition of Oligometastasis Showing Survival Benefits of Local Therapies during Tyrosine Kinase Inhibitor Treatment

• Published in: Cancer research and treatment 2023, 55(2), , pp.468-478
• Main Authors: Jang, Yoon Jung, Hyun, Dong-Gon, Ji, Wonjun, Choi, Chang-Min, Yoon, Shinkyo, Lee, Dae Ho, Kim, Sang-We, Lee, Jae Cheol
• Format: Article
• Language: English
• Subjects: Carcinoma, Non-Small-Cell Lung - pathology; ErbB Receptors - genetics; Humans; Lung Neoplasms - pathology; Mutation; Original; Protein Kinase Inhibitors - therapeutic use; Retrospective Studies; Tyrosine Kinase Inhibitors; 의학일반
• ISSN: 1598-2998; 2005-9256
• DOI: 10.4143/crt.2022.1342

We aimed to investigate the feasibility of four criteria on oligometastasis (OM) concerning clear survival benefits of local therapy (LT) during tyrosine kinase inhibitor (TKI) treatment in non-small cell lung cancer (NSCLC). This single-center, retrospective study included patients with advanced NSCLC who received LT because of OM during TKI treatment at Asan Medical Center from January 2011 to December 2020. At the application of LT OM was classified according to four criteria: TNM, European Organization for Research and Treatment of Cancer Lung Cancer Group (EORTC-LCG), National Comprehensive Network (NCCN), and ORGAN. We compared survival outcomes between patients with and without OM. The median overall survival of the 117 patients included in the analysis was 70.8 months (95% confidence interval [CI], 56.6 to 85.1). The patients with OM meeting all four criteria (hazard ratio [HR] with 95% CI of TNM criteria 0.24 with 0.10-0.57; p=0.001, EORTC-LCG criteria 0.34 with 0.17-0.67; p=0.002, NCCN criteria 0.41 with 0.20-0.86; p=0.018 and ORGAN criteria 0.33 with 0.18-0.60; p < 0.001) had significantly longer survival compared with patients who did not after adjusting for confounding factors. Furthermore, increasing the number of extra-thoracic metastatic organs to two or more were independent predictive factors for worse survival outcomes (2 organs: HR, 3.51; 95% CI, 1.01 to 12.14; p=0.048; 3 organs: HR, 4.31; 95% CI, 0.94 to 19.73; p=0.060; 4 organs: HR, 24.47; 95% CI, 5.08 to 117.80; p < 0.001). Patients with OM defined by all four criteria showed prognostic benefits from LT during TKI therapy.